Objectives: To retrospectively describe the clinicopathological profile and treatment outcome of sex cord ovarian tumours (SCOTs), from a single institution.
Methods: Patients who operated for SCOT between January 2011 and December 2020 were identified from the institution’s discharge summaries. Treatment details and oncologic outcomes were analyzed using descriptive statistics, SPSS statistics version 21. Progression-free survival and overall survival were plotted using the Kaplan–Meier method.
Results: Over 10 years, 120 patients underwent surgery with 73 (61%) malignant SCOTs. Eight (6.6%) were referred with recurrence. Granulosa cell histology (61/73, 83.5%) and federation of gynaecology and obstetrics (FIGO) stage I disease (57/65, 78.62%) were predominant. Three (3/26,11.53%) had lymph node involvement. Adjuvant chemotherapy was advised in 53.4% (39/73).
Over a median period of 47 months (1–130 months), eleven (15.06%) patients recurred (5-year recurrence rate: 9.58%) and 6 died (5-year survival rate: 89.04%).
Among 65 patients with upfront disease, 9 (13.8%) recurred over a median period of 46 months (1–65 months) with 4 disease-related deaths. On univariate analysis, incomplete cytoreduction hazard ratios (HR 58.391, 95% CI 5.042–674.854), advanced FIGO stage (HR 15.931, 3.74–67.89) and nongranulosa histology was associated with recurrence. On multivariate analysis, advanced FIGO stage (HR 20.099, 95% CI 3.75–107.711) and non granulosa histology (HR 31.35, 95% 2.801–350.897 ) remained significant. Lymphadenectomy and adjuvant chemotherapy did not prevent recurrence.
Conclusion: Despite a favourable 5-year survival rate, non granulosa histology and advanced-stage SCOTs pose higher recurrence risks. Personalized decision-making by gynaecologic oncologists is crucial for lymphadenectomies and adjuvant chemotherapy due to unproven benefits. The establishment of rare ovarian tumour registries is encouraged.
